161 studies found for:    anti-EGFR antibodies
Show Display Options
Rank Status Study
1 Completed
Has Results
Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy
Condition: Colorectal Cancer
Intervention: Drug: Everolimus (RAD001)
2 Recruiting BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer
Condition: Cancer
Interventions: Drug: Part 1 Cohort 1: Dabrafenib plus Panitumumab;   Drug: Part 1 Cohort 2: Dabrafenib plus Trametinib plus Panitumumab;   Drug: Part 1 Cohort 3A: Dabrafenib plus Trametinib plus Panitumumab;   Drug: Part 1 Cohort 3B: Dabrafenib plus Trametinib plus Panitumumab;   Drug: Part 1 Cohort 4: Dabrafenib plus Trametinib plus Panitumumab;   Drug: Part 2 Cohort 1: Dabrafenib plus Panitumumab;   Drug: Part 2 Cohort 2: Dabrafenib plus Trametinib plus Panitumumab;   Drug: Part 3 Cohort 1: Dabrafenib plus Panitumumab;   Drug: Part 3 Cohort 2: Dabrafenib plus Trametinib plus Panitumumab;   Drug: Part 3 Cohort 3: 5-fluorouracil-based chemotherapy
3 Terminated Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx, Hypopharynx, or Larynx
Condition: Head and Neck Cancer
Interventions: Biological: cetuximab;   Procedure: conventional surgery;   Radiation: radiation therapy
4 Withdrawn Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients Who Have Undergone Surgery for Advanced Hypopharyngeal Cancer, Oropharyngeal Cancer, Laryngeal Cancer, or Oral Cavity Cancer at High Risk of Recurrence
Condition: Head and Neck Cancer
Interventions: Biological: panitumumab;   Drug: cisplatin;   Drug: fluorouracil;   Other: laboratory biomarker analysis;   Procedure: adjuvant therapy;   Procedure: quality-of-life assessment;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
5 Recruiting Treatment Optimization of Cetuximab in Patients With Metastatic Colorectal Cancer Based on Tumor Uptake of 89Zr-labeled Cetuximab Assessed by PET
Condition: Colorectal Cancer
Intervention: Behavioral: pharmacodynamic purposes of 89Zr-labelled cetuximab and kinase activity profiles
6 Completed
Has Results
Zalutumumab in Patients With Non-curable Head and Neck Cancer
Conditions: Head and Neck Cancer;   Squamous Cell Cancer
Interventions: Drug: Zalutumumab;   Other: Control
7 Unknown  Pre-emptive Low-dose Doxycycline During Anti-EGFR Treatment
Conditions: Colorectal Cancer;   Skin Toxicities
Intervention:
8 Completed Nimotuzumab in Children With Intrinsic Pontine Glioma
Condition: Diffuse Instrinsic Ponitine Glioma
Intervention: Drug: nimotuzumab
9 Recruiting Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus
Conditions: Epidermoid Carcinoma;   Anus
Interventions: Drug: radiochemotherapy;   Drug: Panitumumab
10 Active, not recruiting Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer
Condition: Colorectal Cancer
Interventions: Drug: Irinotecan;   Biological: Cetuximab;   Biological: RAD001
11 Recruiting Phase II Study of Concomitant Intensity-modulated Radiotherapy Combined to Capecitabine, Mitomycin and Panitumumab in Patients With Stage II-IIIB Squamous-cell Carcinoma of the Anal Canal
Condition: Carcinoma of Anal Canal
Interventions: Radiation: RADIOTHERAPY;   Biological: PANITUMUMAB;   Drug: MITOMYCIN;   Drug: CAPECITABINE
12 Recruiting Comparison of Two Preemptive Treatment Strategies of Panitumumab Mediated Skin Toxicity and Assessment of QoL in Patient With Ras-wt Colorectal Cancer
Condition: Ras-wildtype Colorectal Cancer
Interventions: Drug: Erythromycin;   Drug: Doxycycline
13 Recruiting Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects
Conditions: Colorectal Cancer Metastatic;   C-met Overexpression
Intervention: Drug: Tivantinib (ARQ197)
14 Completed Role of FCγRIIIA and FCγRIIA Receptor Polymorphisms
Condition: Upper Gingival Squamous Cell Carcinoma
Intervention: Other: Blood sample for identifying the polymorphism
15 Suspended Hepatic Arterial Chemotherapy With Raltitrexed and Oxaliplatin Versus Capecitabine Plus Mitomycin
Conditions: Colorectal Cancer;   Liver Metastases
Interventions: Drug: oxaliplatin;   Drug: raltitrexed;   Drug: mitomycin C;   Drug: capecitabine
16 Recruiting Cetuximab Plus Radiotherapy Versus Cisplatin Plus Radiotherapy in Locally Advanced Head and Neck Cancer
Conditions: Head and Neck Neoplasms;   Laryngeal Neoplasms;   Mouth Neoplasms;   Pharyngeal Neoplasms
Interventions: Drug: cetuximab (associated with radiotherapy);   Drug: cisplatin (associated to radiotherapy)
17 Recruiting COLOSPOT Study : Assessment by EPISPOT of Circulating Tumor Cells in Patients With Metastatic Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Intervention: Other: Blood analysis by EPISPOT and Cellsearch
18 Active, not recruiting Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy
Condition: Prostate Cancer
Interventions: Drug: etoposide;   Other: laboratory biomarker analysis
19 Not yet recruiting Safety, Tolerability and Pharmacokinetics of Recombinant Anti-epidermal Growth Factor Receptor(EGFR) Monoclonal Antibody in Patients With Metastatic Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Intervention: Biological: Recombinant full human Anti-EGFR Monoclonal Antibody
20 Completed Sym004 in SCCHN Patients Failing Anti-EGFR Based Therapy
Condition: Carcinoma, Squamous Cell of Head and Neck
Intervention: Biological: Sym004

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years